Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1946 1
1955 1
1957 1
1962 5
1963 8
1964 4
1965 6
1966 6
1967 11
1968 6
1969 7
1970 4
1971 4
1972 9
1973 13
1974 5
1975 5
1976 13
1977 13
1978 13
1979 15
1980 24
1981 17
1982 13
1983 16
1984 23
1985 27
1986 18
1987 22
1988 18
1989 19
1990 20
1991 31
1992 36
1993 19
1994 18
1995 23
1996 15
1997 16
1998 19
1999 18
2000 28
2001 37
2002 45
2003 43
2004 61
2005 87
2006 91
2007 104
2008 98
2009 105
2010 147
2011 138
2012 175
2013 207
2014 206
2015 228
2016 222
2017 240
2018 258
2019 260
2020 310
2021 361
2022 372
2023 374
2024 222

Text availability

Article attribute

Article type

Publication date

Search Results

4,475 results

Results by year

Filters applied: . Clear all
Page 1
A review on phytoestrogens: Current status and future direction.
Patra S, Gorai S, Pal S, Ghosh K, Pradhan S, Chakrabarti S. Patra S, et al. Among authors: pal s. Phytother Res. 2023 Jul;37(7):3097-3120. doi: 10.1002/ptr.7861. Epub 2023 May 29. Phytother Res. 2023. PMID: 37246823 Review.
Paraptosis: a unique cell death mode for targeting cancer.
Hanson S, Dharan A, P V J, Pal S, Nair BG, Kar R, Mishra N. Hanson S, et al. Among authors: pal s. Front Pharmacol. 2023 Jun 15;14:1159409. doi: 10.3389/fphar.2023.1159409. eCollection 2023. Front Pharmacol. 2023. PMID: 37397502 Free PMC article. Review.
Melanoma and microbiota: Current understanding and future directions.
Routy B, Jackson T, Mählmann L, Baumgartner CK, Blaser M, Byrd A, Corvaia N, Couts K, Davar D, Derosa L, Hang HC, Hospers G, Isaksen M, Kroemer G, Malard F, McCoy KD, Meisel M, Pal S, Ronai Z, Segal E, Sepich-Poore GD, Shaikh F, Sweis RF, Trinchieri G, van den Brink M, Weersma RK, Whiteson K, Zhao L, McQuade J, Zarour H, Zitvogel L. Routy B, et al. Among authors: pal s. Cancer Cell. 2024 Jan 8;42(1):16-34. doi: 10.1016/j.ccell.2023.12.003. Epub 2023 Dec 28. Cancer Cell. 2024. PMID: 38157864 Free PMC article. Review.
Antimicrobial resistance heterogeneity among multidrug-resistant Gram-negative pathogens: Phenotypic, genotypic, and proteomic analysis.
Mehrotra T, Konar D, Pragasam AK, Kumar S, Jana P, Babele P, Paul D, Purohit A, Tanwar S, Bakshi S, Das S, Verma J, Talukdar D, Narendrakumar L, Kothidar A, Karmakar SP, Chaudhuri S, Pal S, Jain K, Srikanth CV, Sankar MJ, Atmakuri K, Agarwal R, Gaind R, Ballal M, Kammili N, Bhadra RK, Ramamurthy T, Nair GB, Das B. Mehrotra T, et al. Among authors: pal s. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2305465120. doi: 10.1073/pnas.2305465120. Epub 2023 Aug 7. Proc Natl Acad Sci U S A. 2023. PMID: 37549252 Free PMC article.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: pal sk. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Ryan CW, et al. Among authors: pal sk. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28. Lancet. 2023. PMID: 37524096 Clinical Trial.
Lymphatic vasculature in ovarian cancer.
Pal S, Bhowmick S, Sharma A, Sierra-Fonseca JA, Mondal S, Afolabi F, Roy D. Pal S, et al. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188950. doi: 10.1016/j.bbcan.2023.188950. Epub 2023 Jul 5. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37419192 Review.
4,475 results